
Life Saving
Innovation in cancer diagnostics

Simple
Just one blood test

Accurate
Detecting bowel cancer

Non-invasive
Reducing colonoscopies
CanSense is diagnosing bowel cancer early
Bowel (colorectal) cancer is the second most common cancer globally. It is the leading cause of cancer-related death in the Western world. Early diagnosis of bowel cancer significantly reduces mortality rate.
Current diagnostics tests such as colonoscopy or faecal blood detection kits can be invasive, unpleasant and expensive.
We are delivering an accurate, non-invasive, inexpensive blood test to diagnose bowel cancer early.
Delivering one simple blood test
Our focus is delivering a blood test which is equivalent to a liquid biopsy for bowel cancer. We are using a label-free assay and combining laser spectroscopy with advanced data analytics.
The development of a high throughput platform allows our diagnostic solution to be scalable. We continue to develop our product with large scale clinical studies.
At CanSense we ensure accuracy by utilising cutting-edge data analytics and machine learning to maximise the performance of our cancer diagnostic that reduces the need for invasive colonoscopy.

CanSense brings together leading scientists, clinicians and business expertise to deliver the rigour and requirements for diagnostic development.
We are committed to delivering an innovative solution to a major global healthcare problem. Our highly motivated team is focussed on improving patient outcomes in a cost effective manner.
As a University spin-out company we are dedicated to delivering our mission with full impact.